Safety, tolerability and efficacy of a rapid dose escalation of quetiapine in bipolar I mania: the FATIMA study.

Authors:
Eric Constant
Eric Constant
Université Catholique de Louvain
Belgium
Phillippe Snauwaert
Phillippe Snauwaert
4 A.Z. Sint-Lucas-Sint Jozef
Marcel Parent
Marcel Parent
5 Clinique Psychiatrique des Frères Alexiens

Acta Neuropsychiatr 2009 Jun;21(3):125-32

6 AstraZeneca Belgium, Brussels, Belgium.

Objective: The FATIMA study (FAst TItration of quetiapine fumarate in bipolar I MAnia) evaluated the safety, tolerability and efficacy of a rapid dose escalation of quetiapine in acutely ill bipolar I patients experiencing a manic episode.

Methods: In an open-label, phase II pilot study, 29 patients aged 18 years or older, hospitalised with a bipolar I manic episode, received quetiapine twice daily for 21 days. Quetiapine was administered at 200, 400, 600, then 800 mg/day on the first 4 days, with flexible dosing (400-800 mg/day) subsequently. The primary endpoint was the proportion of patient dropouts because of adverse drug reactions during the first 7 days. Secondary safety assessments included incidences of adverse drug reactions and significant changes in vital signs. Efficacy assessments included Young Mania Rating Scale (YMRS) and Clinical Global Impressions Severity of Illness (CGI-S) score changes from day 1 to day 21.

Results: Twenty patients (69%) completed the study. No patients withdrew as a result of drug-related adverse events (AEs) during the first 7 days. Twenty-three patients reported 58 adverse events, and most of the adverse events were mild or moderate. No clinically relevant abnormalities in vital signs were reported. Mean YMRS and CGI-S scores decreased significantly from baseline to day 21 (p < 0.001). Response and remission rates were 78 and 70%, respectively, at the end of the study.

Conclusion: Rapid dose escalation of quetiapine to 800 mg/day over 4 days was well tolerated and effective in reducing symptoms within 5 days in acutely ill bipolar I patients with a manic episode.

Download full-text PDF

Source
http://dx.doi.org/10.1111/j.1601-5215.2009.00378.xDOI Listing

Still can't find the full text of the article?

We can help you send a request to the authors directly.
June 2009
17 Reads

Publication Analysis

Top Keywords

dose escalation
12
escalation quetiapine
12
adverse events
12
rapid dose
12
800 mg/day
8
ill bipolar
8
acutely ill
8
vital signs
8
assessments included
8
mg/day days
8
adverse drug
8
drug reactions
8
fatima study
8
manic episode
8
study patients
8
bipolar patients
8
safety tolerability
8
efficacy rapid
8
bipolar mania
8
tolerability efficacy
8

Similar Publications